MAY 10, 2017 08:00 AM PDT

Optimisation of UCB's Transient Expression Platforms

Speakers
  • Scientist, Protein Sciences, UCB Pharma
    Biography
      After graduation from the Aachen University of Applied Sciences in Germany I worked for a number of years as a Process Development Scientist at AstraZeneca in Sweden in cell line generation and developing scalable fermentation processes for mammalian cell cultures. After this I moved to the UK and joined the New Meds Division of UCB working within the transient gene expression group. Over my 10 years at UCB I have implemented many improvements to both our CHO and HEK293 transient expression platforms which have led to significant improvement in titre and throughput. I am now currently part of the alternative antibody format group helping to design and improve expression of 'difficult to express proteins'.

    Abstract:

    Development of antibody therapeutics, from early stage research to preclinical and clinical development, requires ever-increasing amounts of reagents. To meet the challenge of furnishing a diverse and full pipeline, we utilise several different transient platforms. Through continuous optimisation, streamlining and automation of component parts of our panel of platforms (utilising both HEK293 and CHO host cells with a variety of transfection methods), we now have the capability to produce microgram-to-gram quantities of panels of purified antibodies and antibody fragments in as few as four weeks from receipt of plasmid DNA.


    Show Resources
    You May Also Like
    OCT 02, 2019 11:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    OCT 02, 2019 11:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    MAR 26, 2019 02:00 PM PDT
    C.E. CREDITS
    MAR 26, 2019 02:00 PM PDT
    DATE:  March 26, 2019TIME:  2:00pm PDT, 5:00pm EDT  Prostate cancer is the second most common form of cancer in males, affecting one in eight men by the time t...
    APR 17, 2019 09:00 AM PDT
    C.E. CREDITS
    APR 17, 2019 09:00 AM PDT
    DATE:  April 17, 2019TIME:  9:00am PDT...
    Loading Comments...
    Show Resources